HMG CoA reductase inhibitors and renoprotection: the weight of the evidence

Therapeutic Advances in Cardiovascular Disease
L Romayne KurukulasuriyaJames R Sowers

Abstract

Dyslipidemia and the contributions of oxidized low-density lipoproteins (ox-LDL) are independent cardiovascular risk factors. There is growing evidence that dyslipidemia contributes not only to cardiovascular disease but also to the progressive decline of renal function in diabetic and non-diabetic kidney disease. Ox-LDL, by generating inflammation and oxidative stress, contributes to a pro-atherogenic mileu and leads to endothelial dysfunction, subsequent glomerular filtration barrier damage, and progressive renal injury. Chronic kidney disease (CKD), in turn, induces deleterious effects on lipid metabolism. Therefore, by inhibiting cholesterol synthesis and reducing ox-LDL, HMG CoA reductase inhibitors (statins) are attractive therapeutic options to preserve renal function. Current evidence demonstrates a reduction in cardiovascular risk and improved renal outcomes especially in patients with mild to moderate impairment of renal function. Evidence supports a beneficial role of statins thought to extend beyond their lipid-lowering effect, referred to as pleiotropic actions. These actions include modulatory effects on inflammation, oxidative stress and thrombosis, derived from their ability to prevent the formation of isoprenoi...Continue Reading

References

Aug 1, 1987·The Journal of Clinical Investigation·G UtermannC Seitz
Sep 1, 1993·Kidney International·G GrandalianoH E Abboud
Jan 1, 1993·Kidney International·B H Rovin, L C Tan
Nov 5, 1997·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·O SamuelssonP Alaupovic
Jul 21, 1999·Kidney International. Supplement·H Oda, W F Keane
Jan 5, 2000·Journal of the American Society of Nephrology : JASN·Florian KronenbergArnold VON Eckardstein
May 4, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·C J DeighanC J Packard
Aug 30, 2000·Lancet·C BaigentD Wheeler
Jan 3, 2001·Kidney International·L F FriedB L Kasiske
Feb 13, 2001·Kidney International·C Guijarro, J Egido
Jan 12, 2002·Kidney International·Diana M LeePetar Alaupovic
Jan 12, 2002·Kidney International·Stephen L SeligerCatherine O Stehman-Breen
Jan 24, 2002·Journal of the American Society of Nephrology : JASN·Florian KronenbergArnold von Eckardstein
Feb 16, 2002·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Inga ZelvyteSabina Janciauskiene
Apr 5, 2002·The Journal of Clinical Endocrinology and Metabolism·S I McFarlaneJ R Sowers
Jul 10, 2002·Hypertension·Tsung-Ming LeeChang-Her Tsai
Jan 14, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Wolfgang DichtlFranz Weidinger
Mar 4, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Stefano BianchiVito M Campese
Mar 5, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Sebastian WolfrumJames K Liao
Apr 16, 2003·Kidney International. Supplement·Bengt C FellströmAlan G Jardine
Apr 16, 2003·Kidney International. Supplement·Colin Baigent, Martin Landry
May 23, 2003·Journal of the American Society of Nephrology : JASN·Marcello TonelliUNKNOWN Cholesterol and Recurrent Events Trial Investigators
Jul 23, 2003·Journal of the American Society of Nephrology : JASN·Elke S SchaeffnerJ Michael Gaziano
Oct 29, 2003·Circulation·Mark J SarnakUNKNOWN American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,
Jan 14, 2004·Kidney International·Florian KronenbergHans Dieplinger
Apr 10, 2004·Cardiology·Donald G VidtHoward G Hutchinson
Sep 2, 2004·Journal of the American Society of Nephrology : JASN·Rajiv Agarwal
Feb 8, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Murray Epstein, Vito M Campese
Apr 22, 2005·Journal of the American Society of Nephrology : JASN·Benedetta BussolatiGiovanni Camussi
Jun 7, 2005·Journal of the American Society of Nephrology : JASN·Vito M CampeseMurray Epstein
Jul 22, 2005·The New England Journal of Medicine·Christoph WannerUNKNOWN German Diabetes and Dialysis Study Investigators
Jul 29, 2005·Artificial Organs·Michal ChmielewskiBoleslaw Rutkowski
Aug 18, 2005·Current Atherosclerosis Reports·Donald G Vidt

❮ Previous
Next ❯

Citations

Mar 9, 2013·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Damien Noone, Christoph Licht
Jun 5, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Angelo ZinelluCiriaco Carru
Sep 22, 2009·Clinics in Geriatric Medicine·Anthony J Joseph, Eli A Friedman
Jul 26, 2019·Kardiologiia·E D Kosmacheva, A E Babich
Mar 3, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Yongxia WuFengshuang An

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Clinical Journal of the American Society of Nephrology : CJASN
James ShepherdTreating to New Targets Investigators
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Ola SamuelssonP Alaupovic
© 2021 Meta ULC. All rights reserved